Snowdon

About:

Snowdon Inc. is a pharmaceutical company.

Website: http://snowdonpharma.com/

Top Investors: Foundation Venture Capital Group

Description:

Snowdon Inc. is a pharmaceutical company that is focused on three major therapeutic areas with substantial market potential: acute and chronic pain, neurological disorders, and infectious diseases. These medical conditions cause immense suffering, economic hardship, and loss of life among millions of people every day. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates that address the urgent need for safe and effective medicines. Snowdon’s pipeline extends from NCEs to repurposing off-patent drugs for new clinical indications. The company’s preclinical lead compound, SND-121, has shown exceptional safety and efficacy when administered orally in rodent models as a treatment for neuropathic pain. SND-121 appears to treat pain through a unique mechanism of action, distinct from traditional analgesics such as opioid narcotics, NSAIDs, or the antiepileptics gabapentin and pregabalin.

Total Funding Amount:

$500000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

New Brunswick, New Jersey, United States

Founded Date:

2005-01-01

Contact Email:

info(AT)snowdonpharma.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2007-03-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai